This website isn’t supported by Internet Explorer. We recommend that you use a different browser (e.g. Edge, Chrome, Firefox, Safari, or similar) for the best experience of our content.

Science Hub

Welcome to Novo Nordisk Science Hub

The information on this website is intended for healthcare professionals only and is provided solely for the purpose of scientific exchange. By accessing this website you accept this legal disclaimer and you expressly confirm your status as a healthcare professional.


This website is not country specific and may therefore contain information that is not applicable to your country. The website is not intended to provide medical advice and/or treatment guidance. Therefore, before prescribing any product, always refer to information approved by regulatory authorities in your country such as the prescribing information and/or the Summary of Product Characteristics. Novo Nordisk accepts no liability for the accuracy, completeness or use of information on this website, and disclaims any liability to update the information contained on this website.

Are you a healthcare professional?

During the month of November, Novo Nordisk research was presented at no less than six major congresses. The ScienceHub gives you free access to a comprehensive collection of digital features extending the official congress materials, including audio poster tours, infographics, podcasts, videos featuring our presenters and supplementary slide decks.


We welcome you to explore the science presented at these six conferences.

This year’s ObesityWeek conference once again showcased cutting-edge basic and clinical research in obesity, alongside new insights into how to prevent or treat the highly prevalent disease and its complications. Semaglutide 2.4 mg was featured in multiple oral presentations and on a poster.

The American Society of Nephrology (ASN) this year had a multitude of interesting sessions on new developments in the understanding and management of kidney disease. Exemplifying the challenges faced by companies doing clinical trials during the pandemic, one presentation focused on the operational issues seen for the large FLOW kidney outcomes trial in relation to COVID-19. In addition, kidney-related data from the RESCUE trial with ziltivekimab were shared.

The 2021 AASDL Liver Meeting had a host of exciting sessions on front-line science and developments in liver disease. There were many poster sessions on NASH and how to diagnose, track and treat this prevalent condition, with a focus on fibrosis and on how for example semaglutide and FGF-21 may play a role.

The 14th instalment of the Clinical Trials on Alzheimer's disease (CTAD) brought together key leaders in Alzheimer’s disease (AD) research to discuss the latest therapeutic trials in the neurodegenerative disease, which is characterised by a profound unmet medical need. The ongoing evoke and evoke+ phase 3a trials investigating oral semaglutide in early AD were presented in an oral session.

Also this year, the major global AHA (American Heart Association) meeting was packed with sessions across a wide range of heart-related topics. Reflecting the high interest in this particular heart disease, one presentation focused on the association between BMI and heart failure with preserved ejection fraction. By-age data from the semaglutide CVOTs (SUSTAIN 6 and PIONEER 6) were shared as well.

In a combined meeting, the Network for European CNS Transplantation and Restoration (NECTAR) and International Symposium on Neural Transplantation and Repair (INTR) hosted an international community to disseminate latest research on how to repair the damage to the central nervous system that results from neurodegenerative disease. Central to some of these efforts is the use of human embryonic stem cells as discussed in an oral presentation.